Tradestie Institutional Equity Comparison Engine

ADXN vs PYPD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PYPD Overall Edge

PYPD Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PolyPid Ltd. Ordinary Shares (PYPD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ADXN trades at N/M Forward P/E with -3130.7% operating margin (-72.7% YoY revenue) versus PYPD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ADXN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PYPD sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ADXN N/M vs PYPD N/M Fwd P/E
Growth & Margin Winner PYPD
Op Margin -3130.7% vs 0.0% ยท YoY -72.7% vs +0.0%
Momentum & Technical Winner PYPD
1Y -60.5% vs +81.0% ยท 52W Pos 11% vs 82%
Options & Structure Winner PYPD
UNCLASSIFIED (N/A IV) vs BREAKOUT (12th %ile IV)
ADXN NASDAQ
Addex Therapeutics Ltd American Depositary Shares
Pharmaceutical Preparations
$3.57
-6.79% 1D
Market Cap $7.1M
1M Return +29.35%
1Y Return -60.49%
Forward P/E N/M
Unified AI Score
30.2 / 100 SELL
Tech 3.0 Fund 40.0 Flow 50.0 Mom 60.0
PYPD NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.50
+5.63% 1D
Market Cap $132.2M
1M Return +33.12%
1Y Return +80.95%
Forward P/E N/M
Unified AI Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ADXN -60.49% PYPD +80.95% Spread: +138.8 pp (PYPD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ADXN TTM Op. Margin: -3130.7% PYPD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADXN vs PYPD. Trailing 12-month operating profitability (ADXN -3130.7% vs PYPD 0.0%) and valuation multiples (ADXN N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ADXN (1) vs PYPD (6)
Institutional Metric ADXN PYPD Criterion Row Winner
Market Capitalization Scale $7.1M $132.2M Larger Scale PYPD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -72.7% +0.0% Higher Growth PYPD
Operating Margin (TTM) Profitability -3130.7% 0.0% Higher Margin PYPD
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -150.6% -243.6% Higher ROE ADXN
52-Week Range Position Momentum 11% ($3โ€“$12) 82% ($4โ€“$7) Stronger Trend PYPD
Beta / 30D Volatility Risk Regime 2.28ฮฒ ยท 307% Vol 0.88ฮฒ ยท 59% Vol Lower Realized Risk PYPD
Unified Institutional Score Composite Signal 30.2 / 100 (SELL) 31.1 / 100 (SELL) Higher Composite PYPD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ADXN vs PYPD Buy Guide
ADXN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ADXN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PYPD BREAKOUT
40d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live PYPD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ADXN nor PYPD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.